[{"Assets_0_Q2_USD":1801836000.0,"CommonStockSharesOutstanding_0_Q2_shares":19390.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-15800000.0,"NetIncomeLoss_1_Q2_USD":-14419000.0,"NetIncomeLoss_2_Q2_USD":651918000.0,"StockholdersEquity_0_Q2_USD":1041453000.0,"EarningsPerShareBasic_1_Q2_USD":-0.74,"EarningsPerShareBasic_2_Q2_USD":32.6,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":19558000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":20000000.0,"Ticker":"LGND","CIK":"886163","name":"LIGAND PHARMACEUTICALS INC","OfficialName":"Ligand Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1738856427.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190808"}]